NASDAQ : ALLR

Allarity Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 0.8704 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.85M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Details

NameAllarity Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees8
Founded2004
CeoThomas Jensen
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price0.00
IsinUS0167445008
Cusip016744500
Cik1860657
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Thomas H. JensenFounder, Chief Executive Officer and Director
Dr. Jeremy R. Graff Ph.D.President and Chief Development Officer
Dr. Steen Meier Knudsen Ph.D.Founder and Chief Scientific Officer
Jeffrey S. Ervin M.B.A.Chief Financial Officer
Dr. Jose L. Iglesias M.D.Consultant Chief Medical Officer

Contact

Address123 E. Tarpon Ave., Tarpon Springs, Florida 34689, United States
Phone401 426 4664
Websitehttps://www.allarity.com